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Abstract
Background: Non Obese Diabetic mice lacking B cells (NOD.Igμ
null mice) do not develop diabetes despite their
susceptible background. Upon reconstitution of B cells using a chimera approach, animals start developing
diabetes at 20 weeks of age.
Methods: We have used the spectratyping technique to follow the T cell receptor (TCR) V beta repertoire of NOD.
Igμ
null mice following B cell reconstitution. This technique provides an unbiased approach to understand the
kinetics of TCR expansion. We have also analyzed the TCR repertoire of reconstituted animals receiving
cyclophosphamide treatment and following tissue transplants to identify common aggressive clonotypes.
Results: We found that B cell reconstitution of NOD.Igμ
null mice induces a polyclonal TCR repertoire in the
pancreas 10 weeks later, gradually diversifying to encompass most BV families. Interestingly, these clonotypic BV
expansions are mainly confined to the pancreas and are absent from pancreatic lymph nodes or spleens.
Cyclophosphamide-induced diabetes at 10 weeks post-B cell reconstitution reorganized the predominant TCR
repertoires by removing potential regulatory clonotypes (BV1, BV8 and BV11) and increasing the frequency of
others (BV4, BV5S2, BV9, BV16-20). These same clonotypes are more frequently present in neonatal pancreatic
transplants under the kidney capsule of B-cell reconstituted diabetic NOD.Igμ
null mice, suggesting their higher
invasiveness. Phenotypic analysis of the pancreas-infiltrating lymphocytes during diabetes onset in B cell
reconstituted animals show a predominance of CD19
+ B cells with a B:T lymphocyte ratio of 4:1. In contrast, in
other lymphoid organs (pancreatic lymph nodes and spleens) analyzed by FACS, the B:T ratio was 1:1.
Lymphocytes infiltrating the pancreas secrete large amounts of IL-6 and are of Th1 phenotype after CD3-CD28
stimulation in vitro.
Conclusions: Diabetes in NOD.Igμ
null mice appears to be caused by a polyclonal repertoire of T cell accumulation
in pancreas without much lymphoid organ involvement and is dependent on the help by B cells.
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Introduction
Type 1 diabetes (T1D) is a T cell mediated disease in
which both CD4 and CD8 lymphocytes infiltrate the
islets of Langerhans, causing destruction of insulin-pro-
ducing beta cells and consequently, hyperglycemia.
Many characteristics of human T1D are shared with the
spontaneous onset of disease in inbred Non Obese
Diabetic (NOD) mice, which is commonly used as a
model of human pathology. In NOD mice, T cell islet
infiltration starts within 3-4 weeks of life, ultimately
producing overt diabetes in 80% of female mice beyond
30 weeks of age. Interestingly, NOD.Igμ
null mice (which
are B cell deficient) do not become diabetic [1], but
develop disease if reconstituted with B cells [2]. B cell
reconstitution performed early, at 4 weeks of age by a
chimera approach (to bypass the MHC class I-mediated * Correspondence: cgabaglia@san.rr.com
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starting at 20 weeks of age.
Prior studies have indicated the role of B cells is to
stimulate the auto-reactive T cell repertoire by providing
enhanced antigen presentation and costimulatory capa-
cities that compensate for natural defects in dendritic
cells and macrophage antigen presenting cell popula-
tions in NOD mice [3,4]. It is known that to cause dis-
ease, the B cells are required to possess the I-A
g7 MHC
class II molecule [5] and that the specificity of the B
cells is also important, as reconstitution of HEL-specific
transgenic B cells in NOD.Igμ
null mice did not cause
diabetes [6]. B cell reconstitution has been shown to
restore an autoimmune T cell response to GAD65, an
autoantigen in diabetes, we and others have found to be
important in disease etiology [2,7]. Importantly, NOD.
Igμ
null mice have been shown to contain a functional
autoimmune T cell repertoire (in the absence of B cells)
capable of causing diabetes if transferred into NOD.scid
mice [8].
CDR3 spectratyping or immunoscope analysis is a
highly sensitive technique allowing a non-biased identifi-
cation of the T cell receptor (TCR) repertoire ex-vivo in
target organs, spleen and lymph nodes. Diversity in the
TCR repertoire is the result of random combinations of
V, D and J segments and nucleotide insertions during
recombination. This process results in CDR3 lengths
being generated that are between four and 14 amino
acid residues long. If no T cell expansion is induced
within a particular BV family, a Gaussian distribution of
CDR3 length is observed, typical of background and
polyclonal responses.
In this study, we performed TCR spectratype analysis
of V beta (BV) gene expansions at the BV-C beta level
on NOD.Igμ
null mice in comparison to B cell-reconsti-
tuted NOD.Igμ
null animals, at different time points post-
reconstitution. This allowed us to identify the expanding
TCR repertoire infiltrating the islets of NOD.Igμ
null
mice that are dependent on B cells. We observed that
without B cell reconstitution, NOD.Igμ
null mice had no
pancreatic T cell expansion. No T cell receptor PCR
product across the entire BV family repertoire was
detected, despite Gaussian BV distributions (non-
expanded T cells) being observed in pancreatic lymph
nodes and splenocytes of these animals. However, upon
B cell reconstitution, a progressive infiltration and
increase in diversity of the T cell repertoire was detected
in the pancreases, with most of the BV families present
at pre-diabetic and diabetic stages. A similar expansion
profile of the BV TCR repertoire was also observed in
the pancreas of B cell-reconstituted animals treated with
cyclophosphamide (CYP). CYP treatment produced
accelerated diabetes onset, but no disease in age-
matched unreconstituted NOD.Igμ
null mice. These
results demonstrate that B cells are required for the
generation of a pathogenic repertoire of T cells infiltrat-
ing the pancreas that promote diabetes.
Materials and methods
NOD.Igμ
null mouse B cell chimeras and blood glucose
measurements
NOD.Igμ
null mice (kindly provided by Dr. Serreze, Jack-
son Laboratories-Bar Harbor, ME) were bred in the
TPIMS animal facility. All experiments were performed
under approved TPIMS guidelines for animal care and
use. B cell reconstitution of NOD.Igμ
null mice was per-
formed according to the previously described protocol
of Serreze et al [2]. Briefly, 4 weeks old female NOD.
Igμ
null mice were sub-lethally irradiated (1200 rads)
prior to i.v. injection with 5 × 10
6 cells from syngeneic
age-matched bone marrow (NOD.Igμ
null)a n d3×1 0
6
purified B cells from spleens of 4 weeks old NOD mice.
Control animals received only NOD.Igμ
null syngeneic
bone marrow transplant. Animals were grouped at 4 or
5 per cage and blood glucose levels (Accu-Check Com-
pact Plus, Roche Diagnostics) were determined weekly,
starting at 10 weeks post B cell reconstitution. Three
consecutive blood glucose measurements over 200 mg/
dl were the criteria used as positive determination of
diabetes.
Spectratyping analysis
Tissues were processed from animals at different time
points of disease from whole pancreata, pancreatic
lymph nodes and spleen and spectratyped according to
the protocol of Pannetier et al [9]. Total RNA was iso-
lated from pancreatic tissue or cells isolated from
spleen or lymph nodes, with a Qiagen RNeasy kit (Hil-
den, Germany). cDNA was generated by reverse-tran-
scription using an oligo-dT primer ((dT)15) and
amplified by PCR using a sense primer for each BV
segment and an anti-sense primer (Cbeta145) from the
constant region of the beta chain. The generated PCR
products were denatured in formamide at 92°C and
subjected to analysis on an ABI PRISM 3100 Genetic
Analyzer using GeneMapper v4.0 software (Applied
Biosystems, Foster City, CA). Lengths for each frag-
ment were determined using the Genescan 400HD
ROX size standard (Applied Biosystems). Non-Gaus-
sian peaks representing T cell clonotype expansions
were quantified by dividing the expanded peak area by
the total area of the entire BV expansion spectratype
profile. Only peaks representing 40% or higher of the
total profile area were considered significant expan-
sions in our analysis. When 2 expansions were present,
the area of each peak needed to represent over 30% of
the total area in our analysis, to be considered
significant.
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Pancreatic lymphocytes were isolated as previously
described [10]. Briefly, after performing total animal
body perfusion with 30 ml of PBS, pancreata were har-
vested and cut in small pieces in cold high glucose PBS
supplemented with 5% fetal bovine serum and the tryp-
sin inhibitors, Aprotinin (Sigma) and TCLK (Sigma).
Pancreata were then further digested in warm PBS with
Liberase (Roche) for 20 min at 37°C under gentle agita-
tion and lymphocytes isolated by ficoll gradient before
characterization of surface markers and phenotypic stu-
dies by flow cytometry.
Flow cytometry and phenotypic studies
In flow cytometry, fluorochrome labeled CD3, CD4,
CD8, CD19 and CD44 (supplied by BDSciences, San
Diego, CA) were used for analysis. For the phenotypic
characterization of cytokine production, in vitro stimula-
tion of lymphocytes isolated from pancreas with anti-
CD3 and anti-CD28 beads (Invitrogen Dynabeads) was
performed, and 5 day supernatants were analyzed for
cytokine content by flow cytometry using the CBA kit
screening for IL-2, IL-4, IL-6, IL-10, IL-17, IFNg and
TNFa (BD Biosciences Th1/Th2/Th17 CBA Kit).
Cyclophosphamide depletion of regulatory T cells
Regulatory T cells were depleted by using a 200 mg/kg
dose of cyclophosphamide as previously described [11].
Briefly, 200 μl of a 20 mg/ml saline solution containing
cyclophosphamide (Cytoxan, Mead Johnson, Princeton,
NJ) was administered i.p. to 14 weeks old NOD.Igμ
null
mice that had been reconstituted with B cells. NOD and
unreconstituted age-matched NOD.Igμ
null animals were
used as controls. Cyclophosphamide treatment causes
depletion of regulatory T cells in the pancreas for up to
9 days following treatment [11].
Neonatal NOD.scid transplant under the kidney capsule
Diabetic NOD.Igμ
null mice reconstituted with B cells
were kept alive by subcutaneous insertion of insulin pel-
lets (Linplant, Linshin, Scarborough, Canada) for 2-4
weeks prior to receiving neonatal (24 hours old) pan-
creas transplanted under their kidney capsules. Animals
were sacrificed 40 hours later and the implants were
processed for spectratyping analysis as described above.
Results
Profiles of T1D in NOD.Igμ
null mice reconstituted with
NOD splenic B cells
We studied the progression of diabetes in > 100 NOD.
Igμ
null mice reconstituted with NOD splenic B cells in
comparison to controls (mice receiving NOD.Igμ
null
bone marrow only and naive unreconstituted NOD.
Igμ
null animals). In our facilities, we found a 65%
incidence of diabetes among the B cell-reconstituted
animals, similar to that observed by other groups using
this model [2]. In NOD.Igμ
null B cell reconstituted ani-
mals, the typical time frame for diabetes onset occurred
between 18 to 22 weeks. In some mice disease occurred
as early as 14 weeks and as late as 34 weeks post-recon-
stitution (data not shown). Naïve unreconstituted NOD.
Igμ
null mice or controls (NOD.Igμ
null mice receiving
bone marrow only) did not develop disease up to 34
weeks of age. However, 10% of these mice kept for
long-term observation did develop diabetes very late in
life, beyond 12 months of age! Therefore, onset of T1D
following B cell reconstitution was roughly equivalent to
that as seen for spontaneous disease in the NOD foun-
der strain. A slight delay in disease onset (4 weeks) is
found in B cell reconstituted mice. Lack of disease in
controls clearly indicated a key role for B cells in the
onset of pathology.
Phenotypic analysis of lymphocyte infiltrate in the
pancreata of B cell-reconstituted NOD.Igμ
null mice
Flow cytometry was performed in lymphocytes isolated
from the pancreas by enzyme digestion and ficoll isola-
tion [10]. Because of the low yield of lymphocytes recov-
ered by the isolation technique in younger animals (9
weeks post-reconstitution), only diabetic mice (between
20 and 30 weeks post-reconstitution) were used for flow
cytometric analysis of pancreatic infiltrating lympho-
cytes. Interestingly, we found that CD19
+ B cells repre-
sented the majority of cells infiltrating the pancreases
representing 64 to 74% of total lymphocytic infiltrate.
Only 13-20% of the cells detected were CD3
+ T cells
(Figure 1A). Amongst the CD3
+ T cell compartment,
the composition of the CD4
+ lymphocytes ranged from
50 to 70%, and CD8
+ were 20 to 25%. Approximately
half of the CD4
+ cells and 80% of CD8
+ lymphocytes
detected had a memory marker of CD44
high expression
(Figure 1B). This pattern for the pancreas T cell infiltra-
tion was in stark contrast to pancreatic lymph nodes
and spleens, where the majority of cells were CD44
low
(Figure 1B). Interestingly, the B cell accumulation
observed in the pancreas was not observed in any other
lymphoid organs, including pancreatic lymph nodes and
spleen (Figure 1A).
Next, we determined cytokine secretion profile of
mononuclear cells infiltrating the pancreas. Lympho-
cytes isolated from pancreas were in vitro stimulated
with anti-CD3 and anti-CD28 beads for 5 days. Cytokine
production was evaluated by flow cytometry using cyto-
kine bead assays. Upon CD3 and CD28 stimulation,
high levels of IL-6 cytokine (12,124 pg/ml) were fol-
lowed by IFNg (1,757 pg/ml). Low levels of IL-10 (483
pg/ml), TNFa (163 pg/ml), IL-17 (92 pg/ml) and IL-2
(77 pg/ml) were also detected, while IL-4 (0.29 pg/ml)
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Figure 1 B and Th1 memory lymphocytes accumulate in the pancreas of NOD.Igμ
null mice following B cell reconstitution. A) Flow
cytometry analyses of pancreas infiltrating lymphocytes in diabetic animals (between 20 and 30 weeks post-reconstitution) demonstrated an
accumulation of CD19
+ B cells (74%). T cells accumulate preferentially in pancreatic nodes (73%) and spleen (50%). Data represent 1 of 3
separate experiments with 2-4 animals per group. B) The majority of T cells found infiltrating the pancreas expressed memory marker CD44
high
(80% of CD8
+ and 50% of CD4
+ respectively). C) Pancreas infiltrating lymphocytes were in vitro stimulated with anti-CD3/CD28 beads and 5-day
supernatants were screened by cytokine bead assays (average and SD of 3 animals).
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observed pattern of cytokine production is characteristic
of a Th1 response associated with diabetogenic T cells.
This T cell response is likely the consequence of the
predominance of B cells activating effector T cells infil-
trating the pancreas.
Significant pancreatic TCR expansions are dependent
upon B cell reconstitution in NOD.Igμ
null mice
Because of the already described role of T cells causing
T1D, pancreata from NOD.Igμ
null mice were used for
spectratyping analysis and detection of T cell receptor
V beta chain (BV) expansions at different time points
between 5 to 22 weeks of age. Spleen and pancreatic
lymph nodes isolated from the majority of NOD.Igμ
null
mice presented only Gaussian distributions across
every BV family tested. An example profile is demon-
strated in Figure 2 for BV2, 10, 12, 14 in 14 week-old
NOD.Igμ
null mice (PLN-pancreatic lymph nodes and
SP-spleens). In the majority of the unreconstituted
NOD.Igμ
null animals, pancreatic tissue did not generate
any detectable PCR product for most BV-TCR families,
or presented rare Gaussian expansions (Figure 2).
These results indicated that T cells had not infiltrated
or were not clonally expanded in the pancreas in the
absence of B cells. In contrast, clonotypic expansions
were observed in the pancreases of NOD.Igμ
null mice
at 10 weeks after B cell-reconstitution, indicating a
role for B cells in the recruitment and expansion of
pathogenic T cells (Figure 2).
Predominant TCR expansion peaks were detected by
spectratyping in BV2, 10, 12, 14, 18, 19 and 20 in B cell
reconstituted NOD.Igμ
null mice. Interestingly, this TCR
expansion (non-Gaussian BVs) was specific to the pan-
creas, as pancreatic lymph nodes and spleens from these
animals only produced Gaussian distributions for these
same BV families. Total cell numbers recovered from
pancreatic lymph nodes were unchanged following B
cell reconstitution (data not shown) suggesting that the
T cell autoimmune response precipitating diabetes do
not appear to be expanding in lymphoid organs.
B cell reconstitution of NOD.Igμ
null mice promotes
progressive expansion of the TCR repertoire in the
pancreas
To follow the progression of T cell infiltration after B
cell reconstitution of NOD.Igμ
null mice, the animals
were spectratyped at different time points. At early time
points, 9-10 weeks post-B cell reconstitution, the major-
ity of the reconstituted animals accumulated BV2, BV10,
12 and 14 in the pancreas (Figure 3A). At intermediate
time points (13-16 weeks post-reconstitution), and even
later pre-diabetic and diabetic stages (19-31 weeks post-
reconstitution), an increase in the number of BV
families was observed. In particular, members of the
BV16 to 20 TCR repertoire were present at later time
points (Figures 3B and 3C). These results demonstrate
that B cell reconstitution is required before a progressive
T cell infiltrate is found in the pancreas. The initial TCR
repertoire infiltrating the pancreas is less diverse, but
ultimately expands over time during diabetogenesis to
include a much broader TCR repertoire. This finding is
consistent with the spreading and diversification of the
pathogenic T cell repertoire [12,13].
B cell reconstituted NOD.Igμ
null mice develop accelerated
diabetes following cyclophosphamide-treatment
To better understand the functionality of the TCR
expanded repertoire promoted by B cell reconstitution
in NOD.Igμ
null mice, we made use of the cyclophospha-
mide-accelerated diabetes model. Cyclophosphamide
(CYP) has been shown to deplete the subset of T cells
with regulatory function and accelerate diabetes in NOD
mice [11]. We tested whether 14 week-old ureconsti-
tuted NOD.Igμ
null mice could also develop accelerated
disease. Interestingly, we found these animals were resis-
tant to CYP-accelerated diabetes. However, in B-cell
Figure 2 Representative comparative spectratype analysis for
BV families found in spleens, pancreatic lymph nodes and
pancreas from untreated and B-cell reconstituted NOD.Igμ
null
mice. Splenocytes (SP) and Pancreatic lymph nodes (PLN) were
analyzed from naïve NOD.Igμ
null and B cell-reconstituted mice (NOD.
Igμ
null + B cells). Gaussian profiles for BV2, BV10, BV12 and BV14
families were found in spleens and lymph nodes. Pancreata (PN) of
naïve NOD.Igμ
null animals had no expansions for these clonotypes,
but non-gaussian expansions were detected in high frequency
following B cell reconstitution.
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sickness with increased percentages of afflicted animals,
compared to age-matched NOD controls (data not
shown). We spectratyped the T cell repertoire in the
pancreata following CYP-treatment (Figure 4), and
found a decrease and/or loss of BV1, BV8 and BV11
TCR expansions. These families are normally present at
this time point in B cell reconstituted untreated NOD.
Igμ
null mice, indicating their potential regulatory func-
tion. Furthermore, increased expansions in BV4, BV5.2
and BV9 repertoires were found after CYP treatment, as
well as additional expansions of the BV16 to BV20
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Figure 3 Policlonal BV repertoire expansions are found in the pancreata following B cell reconstitution in NOD.Igμ
null mice. A)
Spectratype analysis of BV-BC (Vbeta-Cbeta) expansions for pancreas-infiltrating T cells 10 weeks post-B cell reconstitution demonstrate a
polyclonal profile of induced clonotypes, with BV2, BV10, BV12 and BV14 being present on over 60% of the animals, followed next in appearance
by BV8S3 and BV11, present in 50% of the mice. B) As disease progresses, a higher diversity of clonotypes is observed, particularly for the
appearance of BV16, BV17, BV18, BV19 and BV20 in 13-16 weeks post-reconstitution and later C) at pre-diabetic stages (19-31 weeks post-
reconstitution).
Vong et al. Journal of Translational Medicine 2011, 9:101
http://www.translational-medicine.com/content/9/1/101
Page 6 of 10subsets of T cells, in comparison to age-matched B-cell
reconstituted NOD.Igμ
null animals. These expansions
include BV families directed against antigens proposed
as targets of autoimmune response in diabetes patho-
genesis [7,14].
Pancreatic implants into diabetic NOD.Igμ
null mice reveal
early invasive expansions in select BV clonotypes during
tissue rejection
To search for most aggressive/invasive BV expansions, we
studied the pancreatic-graft rejection model. We reasoned
that the repertoire potentially mediating early-graft rejec-
tion could be as important in initiating T1D. In this
model, neonatal NOD.scid pancreases were implanted
under the kidney capsule of diabetic B cell reconstituted
NOD.Igμ
null mice. After developing diabetes, mice were
kept alive by subcutaneous administration of insulin pel-
lets for 2-4 weeks to stabilize their glycemic levels prior to
implantation of neonatal NOD.scid pancreas under their
kidney capsule. After 40 hours, implants were removed for
spectratyping analysis of TCR repertoire of infiltrating T
cells. Earlier studies suggested this time point to be the
best for examining implant infiltrate, before rejection and
fibrosis. Spectratyping analysis of the implants (Figure 5)
revealed polyclonal expansions, with several TCR families
( B V 1 ,2 ,4 ,5 . 2 ,8 . 3 ,1 0a n d1 5 )b e i n gp r e s e n ti nm o s to f
the implants, including BVs suspected to be of regulatory
phenotype based on the cyclophosphamide experiments
(Figure 4). Except for BV10, present in similar frequency
in the implants and the pancreas, these BV families were
found in higher frequencies in the implants, suggesting
their higher invasiveness.
Discussion
Previous studies examining T cell responses and reper-
toire analysis involved in the autoimmune response of
diabetes have produced conflicting results related to the
identification of the pathogenic T cell repertoire. Some
groups have described polyclonal T cell expansions aris-
ing very early in the pancreas being responsible for islet
destruction, [15,16], while others have claimed that only
particular clonal expansions are the driving force behind
autoimmune responses in diabetes [17,18].
These variable findings likely reflect the different tech-
niques employed to characterize T cell responses in the
pancreas during the course of spontaneous disease. Here
we have employed spectratyping analysis to detect T cell
expansions ex-vivo, in a non-biased attempt at examin-
ing the T cell responses in the pancreas following B cell
reconstitution in NOD.Igμ
null mice. We found that by 9-
10 weeks post-B cell reconstitution, the majority of the
animals present pancreatic TCR expansions (at 13
weeks of life). Of note, these animals do not have clono-
typic expansions in their pancreatic lymph nodes or
spleens, suggesting that clonotypic TCR expansions in
lymphoid organs are not involved in disease induction
(Figure 2). The initial pancreatic T cell infiltration con-
sisted of several clonotypes, including BV2, BV10, and
BV12, clonotypes already described as reactive to insulin
or GAD65 [7,14]. BV12 has been found to be enriched
in islets of NOD mice when compared to thymus and
spleens [15,19]. We also found a BV15 expansion that is
a possible candidate for BDC-10.1, a chromogranin A-
reactive BV15 T cell [20], which had been previously
characterized with a high diabetogenic capacity [14]. As
disease progressed, an even larger TCR repertoire infil-
trating the organ was observed. This finding is consis-
tent with spreading of the T cell response [21].
Considering the ever-growing list of islet antigens
described as being targets of autoimmune response in
T1D this polyclonality is expected [17,22]. We found
that during the pre-diabetic and diabetic stages,
 
 
 
 
 
Figure 4 Spectratyping profile of B cell-reconstituted NOD.Igμ
null mice following cyclophosphamide treatment. Spectratype analysis of
BV-BC expansions for pancreas-infiltrating T cells at 10 weeks post-B cell reconstitution of NOD.Igμ
null mice are shown, following treatment with
cyclophosphamide (black bars) in comparison to 10 weeks old age-matched of NOD.Igμ
null mice reconstituted with B cells (white bars), and
diabetic NOD.Igμ
null mice reconstituted with B cells (grey bars).
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families were commonly detected, but these were not
predominant in early infiltrates (Figure 3A). It is possi-
b l es o m eo ft h e s ee x p a n s i o n sc o u l dc o m p r i s ea l r e a d y
described pathogenic clones. A BV16 GAD65-reactive
clone (11H11) has been found in the islets of pre-dia-
betic NOD, with the distinct promiscuous capacity of
recognizing different GAD65 peptides using a single
TCR [23].
In attempts to find commonalities in clonotype expan-
sions in different pathological states of islet infiltration
in the B cell reconstituted NOD.Igμ
null model, we also
examined the cyclophosphamide-accelerated diabetes
and the rejection of pancreatic implants in diabetic
NOD.Igμ
null B cell reconstituted mice. Following cyclo-
phosphamide treatment, known to eliminate regulatory
T cells from the pancreas [11], we found the pancreas-
infiltrating repertoire to be quite distinct from that of
age-matched non-diabetic NOD.Igμ
null Bc e l lr e c o n s t i -
tuted mice, demonstrating that some regulatory compo-
nent is also promoted by B cell reconstitution.
Interestingly, BV1, BV8 and BV11 T cell expansions
were greatly reduced or lost, while a new set of BV4,
BV5S2, BV9 and BV16-20 expansions arose, suggesting
their role in pathogenicity. Furthermore, BV8S1 and
BV8S2 are absent in the cyclophosphamide treated
group (a treatment known to destroy regulatory T cells),
but present in 50% of the B cell-reconstituted animals.
BV8S1 has been previously described as a predominant
clonotype infiltrating the islets of partially diabetes-resis-
tant male NOD mice [24] and, interestingly, is also pre-
sent in the blood of T1D patients [25]. This may
indicate that some regulatory component may still be
present, although ineffective, at final diseased stages
post-B cell reconstitution.
In another approach to address the identity of the
pathogenic repertoire, we examined the infiltrating T
cells rejecting new pancreatic implants (Figure 5). Pan-
creatic tissue from neonatal NOD.scids transplanted
under the kidney capsule of diabetic B cell reconstituted
NOD.Igμ
null mice were rejected very fast (within 4 days),
with the peak of T cell infiltration occurring within 2
days after implantation. The spectratype profile of the
BV repertoire from day 2 implants (Figure 5, black bars)
was very similar to that seen in the diabetic pancreas
(Figure 5, grey bars) but with over 70% of the implants
presenting BV1, BV2, BV4, BV5S2, BV8S3, BV10 and
BV15 clonotypes. Interestingly, BV1 and BV8 clonotypes
were decreased by cyclophosphamide treatment (Figure
4, black bars), therefore, with potential regulatory func-
tion. These findings indicate that in B cell reconstituted
NOD.Igμ
null mice, highly invasive clonotypes predomi-
nantly infiltrating transplants are composed of particu-
larly high pathogenic effectors, as well as regulatory T
cells.
The breaking of T cell tolerance and passage through
“Checkpoint 1-End of Ignorance” [26] by B cell reconsti-
tution, may result owing to two different possibilities.
First, homeostatic proliferation of pathogenic T cells fol-
lowing sublethal irradiation, could awaken autoimmune
responses. Homeostatic proliferation in an immunodefi-
cient host due to sublethal irradiation or in NOD.scid
recipients, follows a pattern of expansion that takes
circa 6 weeks for complete reconstitution [14]. This
Figure 5 Spectratyping profile of lymphocytes infiltrating neonatal pancreas implanted under the kidney capsule of diabetic B cell-
reconstituted NOD.Igμ
null mice. Spectratyping analysis of BV-BC of neonatal NOD.scid pancreas transplanted under the kidney capsule of
diabetic NOD.Igμ
null mice reconstituted with B cells (black bars). Spectratyping profile of pancreata from diabetic B cell-reconstituted NOD.Igμ
null
(grey bars).
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autoimmune responses [8,27]. Second, autoimmunity
could be mediated by the expansion of a T cell reper-
toire remodeled by the presence of B cells, through their
unique antigenic display and enhanced proinflammatory
and costimulatory capacities. We argue that homeostatic
proliferation seems less likely, as T cells from control
animals (reconstituted with bone marrow following irra-
diation) also go through homeostatic proliferation but
do not develop diabetes! B cells from NOD mice are
known to produce strong inflammatory responses, when
compared to other non-autoimmune strains [28] and
present higher levels of costimulatory molecules [29].
Therefore, our data describing a B:T cell ratio of 4 in
the pancreases support the second mechanism, and the
role for B cells as an important antigen presenting cells
in NOD.Igμ
null m i c e .I ti sl i k e l yt h a tBc e l l sh e l pi nt h e
induction/activation of the autoreactive TCR repertoire.
During diabetes promoted after B cell reconstitution
in NOD.Igμ
null mice, B cells encompass over 64% of the
lymphocyte population infiltrating the pancreas, despite
equal numbers of B and T cells in the other lymphoid
organs analyzed (spleens and pancreatic lymph nodes).
Interestingly, recent study on the cellularity composition
of individual pancreatic islets in female and male NOD
mice at different time points of disease evolution do not
report a high accumulation of B cells in the pancreas
when compared to lymphoid organs [30], while another
study identify comparable B:T cell ratios in the spleen
for NOD animals [5]. The accumulation of B cells in
the pancreas of NOD.Igμ
null reconstituted mice could
bypass the requirement for T cell lymph node recruit-
ment and may help explain why clonotypic T cell
expansions detected in the pancreas are not likewise
present in adjacent pancreatic lymph nodes by spectra-
typing studies. The autoimmune responses may be pre-
ferentially localized to the pancreas, induced by larger
numbers of antigen presenting B cells (B:T ratio of 4)
which could be promoting the effector T cell repertoires
unbalancing the regulatory clonotypes. The number of
CD19
+ B cells circulating in blood post-reconstitution in
NOD.Igμ
null mice varied from 1 to 13%, with no correla-
tion of higher blood B cells and diabetes onset (data not
shown). B cell accumulation in the pancreases but not
in lymphoid organs, suggest that the direct activation of
effector T cells in the target organ by B cells may be the
crucial trigger for disease induction.
B cell accumulation in the pancreas appears to main-
tain CD4 and CD8 lymphocytes in an activated state
(CD44
high Figure 1) and IL-6 secreted by the mononuc-
lear pancreatic infiltrate could modulate T cell activity.
IL-6 is known to alter phagolysosomal processing, enhan-
cing presentation of cryptic antigenic determinants [31]
and to provide survival signal for T cells [32]. Thus,
reintroduction of B cells appear to provide an ideal envir-
onment for pathogenic T cell activation and survival.
Conclusions
This study demonstrates that a polyclonal repertoire of
pathogenic T cell expansion is dependent upon B cell
reconstitution in NOD.Igμ
null mice. Diabetes progression
appears to be facilitated by B cell accumulation in the
pancreas. Interestingly, the clonotypic T cell expansion
observed in the pancreas is not observed in other tradi-
tionally involved lymphoid organs, including the pan-
creatic lymph nodes and spleen. The dependence on B
cells for the appearance of the pathogenic repertoire of
T cells infiltrating the pancreas may help explain why
current therapies targeting B cells can affect T1D in
NOD mice and humans [33].
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